COPD Clinical Trial Landscape
Data updated: May 20, 2026
1,171 clinical trials tracked since 2008
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that obstructs airflow, making breathing difficult. It primarily affects adults and is a major cause of chronic morbidity and mortality worldwide. The COPD clinical trial landscape includes 1,167 registered trials since 2008, with 127 trials currently active, meaning they are recruiting, enrolling, or active but not recruiting patients. Activity is distributed across all phases, with 26 active Phase 1, 57 active Phase 2, 34 active Phase 3, and 25 active Phase 4 trials. The distribution shows a notable concentration of trials in Phase 2. AstraZeneca leads industry sponsorship of active trials with 9, followed by GSK and Chia Tai Tianqing Pharmaceutical Group Co., Ltd., each with 5 active trials. Sanofi sponsors 4 active trials, and Roche sponsors 3.
130 active
/
1171 total (since 2008)
27
Phase 1 Active
251 total
56
Phase 2 Active
357 total
35
Phase 3 Active
346 total
27
Phase 4 Active
278 total
Top Industry Sponsors
Sorted by active Active Done Failed
AstraZeneca 10 99 9
GSK 5 158 6
Sanofi 4 7 0
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 4 4 2
Haisco Pharmaceutical Group Co., Ltd. 4 2 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06283966 RECRUITING
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
AstraZeneca n=5,000
NCT07190222 RECRUITING
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Sanofi n=942
NCT07190209 RECRUITING
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi n=942
NCT06878261 RECRUITING
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
AstraZeneca n=990
NCT06883305 RECRUITING
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
AstraZeneca n=990
+ 341 more Phase 3 trials — see full database below
COPD — Trials Started by Year (last 10 years)
2016 64
2017 66
2018 45
2019 33
2020 31
2021 32
2022 34
2023 37
2024 42
2025 58
2026 22
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
AstraZeneca 118
GSK 169
Sanofi 11
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 10
Haisco Pharmaceutical Group Co., Ltd. 6
Roche 8
Joincare Pharmaceutical Group Industry Co., Ltd 4
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA 14
Mabwell (Shanghai) Bioscience Co., Ltd. 4
Guangdong Hengrui Pharmaceutical Co., Ltd 3
Active Trials by Phase
Phase 1 27
Phase 2 56
Phase 3 35
Phase 4 27
Enrollment Size Distribution
1-50 421
51-200 332
201-500 164
501-1k 110
1k+ 97
All Industry Sponsors
Sorted by active Active Done Failed
AstraZeneca 10 99 9
GSK 5 158 6
Sanofi 4 7 0
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 4 4 2
Haisco Pharmaceutical Group Co., Ltd. 4 2 0
Roche 3 3 2
Joincare Pharmaceutical Group Industry Co., Ltd 3 1 0
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA 2 12 0
Mabwell (Shanghai) Bioscience Co., Ltd. 2 2 0
Guangdong Hengrui Pharmaceutical Co., Ltd 2 1 0
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 2 0 0
Bambusa Therapeutics 2 0 0
Pfizer 1 9 1
Merck 1 1 2
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 1 1 0
NCT06283966 RECRUITING
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
AstraZeneca n=5,000
NCT07583849 NOT YET RECRUITING
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD
Haisco Pharmaceutical Group Co., Ltd. n=376
NCT07190222 RECRUITING
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Sanofi n=942
NCT07190209 RECRUITING
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi n=942
NCT06878261 RECRUITING
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
AstraZeneca n=990
NCT06883305 RECRUITING
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
AstraZeneca n=990
NCT05878769 RECRUITING
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Hoffmann-La Roche n=2,000
NCT07566195 NOT YET RECRUITING
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
AstraZeneca n=82
NCT06961214 RECRUITING
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
GlaxoSmithKline n=960
NCT05595642 ACTIVE NOT RECRUITING
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche n=1,290
NCT07456176 NOT YET RECRUITING
Effect of Low-Dose Versus High-Dose Alpha-Lipoic Acid on Oxidative Stress, Inflammation, and Clinical Outcomes in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Ain Shams University n=75
NCT07363694 RECRUITING
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer n=1,156
NCT06040086 ACTIVE NOT RECRUITING
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
AstraZeneca n=1,454
NCT05265299 RECRUITING
Trial to Determine Effective Aspirin Dose in COPD
Johns Hopkins University n=48
NCT05742802 ACTIVE NOT RECRUITING
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
AstraZeneca n=1,713
NCT07464587 NOT YET RECRUITING
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=800
NCT07330310 NOT YET RECRUITING
A Phase 3 Trial of JKN2401 Injection in COPD
Joincare Pharmaceutical Group Industry Co., Ltd n=888
NCT05844462 RECRUITING
Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
Assistance Publique - Hôpitaux de Paris n=200
NCT07177339 RECRUITING
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
GlaxoSmithKline n=1,196
NCT07039669 RECRUITING
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. n=594
NCT06376994 RECRUITING
Multi-Center Clean Air Randomized Controlled Trial in COPD
JHSPH Center for Clinical Trials n=770
NCT06959095 RECRUITING
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
GlaxoSmithKline n=981
NCT07147946 NOT YET RECRUITING
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=666
NCT07047092 NOT YET RECRUITING
Non-invasive Ventilation or CPAP in OSA-COPD Following Admission for an Acute Hypercapnic Respiratory Failure
Assistance Publique - Hôpitaux de Paris n=386
NCT06208306 ACTIVE NOT RECRUITING
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Sanofi n=700
NCT06999343 NOT YET RECRUITING
Exploring the Anti-ageing Effects of Metformin in COPD
Fundación Instituto de Investigación Sanitaria de Navarra n=212
NCT06474039 RECRUITING
The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD
Mahidol University n=50
NCT02984124 ACTIVE NOT RECRUITING
Communication During Hospitalization About Resuscitation Trial
University of Vermont n=182
NCT06234345 NOT YET RECRUITING
Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)
Eurofarma Laboratorios S.A. n=1,252
NCT06347536 RECRUITING
Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease
Guy's and St Thomas' NHS Foundation Trust n=1,400
NCT06785337 RECRUITING
"The Effect of Inhaled Nitroglycerin for COPD Patients
Beni-Suef University n=40
NCT06547333 NOT YET RECRUITING
A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=884
NCT06212765 NOT YET RECRUITING
Oral Citrulline Supplementation in COPD Patients With Malnutrition
University Hospital, Grenoble n=60
NCT04018729 RECRUITING
Cell Therapy Associated With Endobronchial Valve
Hospital de Clinicas de Porto Alegre n=34
NCT03888131 COMPLETED
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)
Chiesi Farmaceutici S.p.A. n=750
NCT05138250 COMPLETED
A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD
Sheffield Teaching Hospitals NHS Foundation Trust n=31
NCT04075331 COMPLETED
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
University of Leicester n=238
NCT05166889 COMPLETED
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
AstraZeneca n=1,132
NCT05158387 COMPLETED
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
AstraZeneca n=1,172
NCT04751487 COMPLETED
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi n=1,239
NCT04701983 COMPLETED
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi n=1,127
NCT04876677 COMPLETED
Functional Respiratory Imaging Study (DARWiIN)
Chiesi Farmaceutici S.p.A. n=25
NCT03794583 TERMINATED
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
United Therapeutics n=41
NCT06643078 COMPLETED
A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients With COPD
Haisco Pharmaceutical Group Co., Ltd. n=487
NCT04004117 TERMINATED
Effect of Sublingual Fentanyl on Breathlessness in COPD
McGill University Health Centre/Research Institute of the McGill University Health Centre n=40
NCT06067828 COMPLETED
A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).
AstraZeneca n=171
NCT04636814 TERMINATED
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Chiesi Farmaceutici S.p.A. n=3,973
NCT04320342 COMPLETED
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
Chiesi Farmaceutici S.p.A. n=3,433
NCT04636801 TERMINATED
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)
Chiesi Farmaceutici S.p.A. n=4,710
NCT01842360 COMPLETED
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
Inmunotek S.L. n=198
NCT05573464 COMPLETED
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
AstraZeneca n=559
NCT02683668 COMPLETED
Airway Effects of Tiotropium in Patients With COPD
Imperial College London n=44
NCT06075095 COMPLETED
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD
AstraZeneca n=297
NCT04053634 COMPLETED
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
AstraZeneca n=689
NCT04133909 COMPLETED
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level
GlaxoSmithKline n=806
NCT05743075 COMPLETED
A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Nuance Pharma (shanghai) Co., Ltd n=526
NCT04456673 COMPLETED
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Sanofi n=935
NCT06460493 COMPLETED
Effect of Ensifentrine Treatment on CAT Score
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA n=20
NCT03022097 COMPLETED
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
AstraZeneca n=1,625
NCT03956888 COMPLETED
The Anti-oxidant Effects of N-Acetylcysteine in Chronic Obstructive Pulmonary Disease (COPD)
Siriraj Hospital n=35
NCT02887521 TERMINATED
Pulmonary Rehabilitation Before Lung Cancer Resection
Alliance for Clinical Trials in Oncology n=9
NCT03984188 COMPLETED
Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD
University of Miami n=100
NCT04517500 COMPLETED
A Home-based Module to Promote Mindful Breathing Awareness for COPD Patients
Mayo Clinic n=99
NCT05046795 COMPLETED
Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
Mylan Pharma UK Ltd. n=258
NCT00604500 COMPLETED
A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)
Organon and Co n=272
NCT03930732 COMPLETED
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
Sanofi n=939
NCT05986591 COMPLETED
Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Xiromed LLC n=335
NCT03496623 TERMINATED
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
United Therapeutics n=188
NCT04535986 COMPLETED
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA n=763
NCT04542057 COMPLETED
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA n=790
NCT00662740 TERMINATED
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
Boehringer Ingelheim n=220
NCT05927155 COMPLETED
Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD
Erasme University Hospital n=30
NCT02867761 COMPLETED
RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
University of Michigan n=780
NCT05161156 COMPLETED
Bioequivalence Study of Tiotropium Bromide Inhalation Powder
Phargentis SA n=306
NCT00662792 COMPLETED
Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD
Boehringer Ingelheim n=147
NCT04078126 COMPLETED
Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
AstraZeneca n=35
NCT02512510 COMPLETED
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
Mylan Inc. n=611
NCT02518139 COMPLETED
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
Mylan Inc. n=1,060
NCT03573817 COMPLETED
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
Mylan Inc. n=122
NCT02459080 COMPLETED
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
Mylan Inc. n=619
NCT03674320 WITHDRAWN
Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD
The University of Texas Medical Branch, Galveston
NCT03256695 COMPLETED
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Teva Branded Pharmaceutical Products R&D, Inc. n=405
NCT01917331 COMPLETED
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
Chiesi Farmaceutici S.p.A. n=1,368
NCT00929851 COMPLETED
BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)
Chiesi Farmaceutici S.p.A. n=1,199
NCT02467452 COMPLETED
Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
Chiesi Farmaceutici S.p.A. n=1,479
NCT01911364 COMPLETED
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease
Chiesi Farmaceutici S.p.A. n=3,686
NCT02579850 COMPLETED
2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients
Chiesi Farmaceutici S.p.A. n=1,532
NCT04446637 WITHDRAWN
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
Neutec Ar-Ge San ve Tic A.Ş
NCT02722304 TERMINATED
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
Baxalta now part of Shire n=7
NCT04879030 COMPLETED
Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD
Haiphong University of Medicine and Pharmacy n=170
NCT03137992 COMPLETED
Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness
Lupin, Inc. n=377
NCT03197818 COMPLETED
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Chiesi Farmaceutici S.p.A. n=990
NCT02536508 COMPLETED
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Pearl Therapeutics, Inc. n=627
NCT03836677 COMPLETED
A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
AstraZeneca n=23
NCT02465567 COMPLETED
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
Pearl Therapeutics, Inc. n=8,588
NCT02587351 TERMINATED
Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
University of Minnesota n=532
NCT03324607 COMPLETED
Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI
Bastiaan Driehuys n=20
NCT03379233 TERMINATED
A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence
Novartis Pharmaceuticals n=7
NCT02497001 COMPLETED
A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
Pearl Therapeutics, Inc. n=1,902
NCT02067780 COMPLETED
Short Antibiotic Treatment Versus Duration Guided by Markers of Inflammation in the Treatment of AECOPD
University of Monastir n=310
NCT04479930 COMPLETED
Effects of an mHealth Web-Based Platform (HappyAir) on Adherence to a Maintenance Program After Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease
CEU San Pablo University n=44
NCT02184611 COMPLETED
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)
GlaxoSmithKline n=308
NCT04361552 WITHDRAWN
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Emory University
NCT03262012 COMPLETED
Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®
Pearl Therapeutics, Inc. n=416
NCT01973998 COMPLETED
Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization
Temple University n=68
NCT01509677 COMPLETED
Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
AstraZeneca n=158
NCT04122547 COMPLETED
Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis
Prince of Songkla University n=40
NCT02685293 TERMINATED
Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD
Pearl Therapeutics, Inc. n=4
NCT01423227 COMPLETED
Benefits and Costs of Home-based Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease
La Trobe University n=144
NCT02937584 COMPLETED
A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD
Pearl Therapeutics, Inc. n=23
NCT02729051 COMPLETED
Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=1,055
NCT02155660 COMPLETED
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
AstraZeneca n=2,255
NCT02138916 COMPLETED
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
AstraZeneca n=1,656
NCT02629965 COMPLETED
Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
Boehringer Ingelheim n=184
NCT03162055 COMPLETED
Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
AstraZeneca n=1,119
NCT02888444 TERMINATED
Smoking Relapse Prevention Among COPD Ex-smokers
University of Auckland, New Zealand n=8
NCT02643082 COMPLETED
A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
Pearl Therapeutics, Inc. n=20
NCT02343458 COMPLETED
Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
Pearl Therapeutics, Inc. n=1,756
NCT01946620 COMPLETED
A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD
Mundipharma Research Limited n=1,767
NCT02164513 COMPLETED
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=10,355
NCT02135354 TERMINATED
Azithromycin for Acute Exacerbations Requiring Hospitalization
Wim Janssens n=301
NCT01342913 COMPLETED
A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))
GlaxoSmithKline n=528
NCT02105948 COMPLETED
Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
GlaxoSmithKline n=837
NCT01017952 COMPLETED
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=1,635
NCT02105961 COMPLETED
Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=674
NCT01313676 COMPLETED
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
GlaxoSmithKline n=16,568
NCT01313650 COMPLETED
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
GlaxoSmithKline n=1,538
NCT03081247 WITHDRAWN
To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Pearl Therapeutics, Inc.
NCT02347085 COMPLETED
24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI
Pearl Therapeutics, Inc. n=43
NCT02345161 COMPLETED
A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=1,811
NCT01053988 COMPLETED
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=1,031
NCT02296138 COMPLETED
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
Boehringer Ingelheim n=7,903
NCT01316887 COMPLETED
A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=563
NCT01706328 COMPLETED
A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=828
NCT02487498 COMPLETED
Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
Novartis Pharmaceuticals n=355
NCT02347761 COMPLETED
Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD
Sunovion Respiratory Development Inc. n=653
NCT02276222 COMPLETED
A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD
Sunovion Respiratory Development Inc. n=1,087
NCT02347774 COMPLETED
Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)
Sunovion Respiratory Development Inc. n=641
NCT02257385 COMPLETED
Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium
GlaxoSmithKline n=967
NCT02014480 COMPLETED
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=207
NCT01395888 COMPLETED
A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD
GlaxoSmithKline n=260
NCT01323621 COMPLETED
Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=512
NCT01323660 COMPLETED
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
GlaxoSmithKline n=307
NCT01772134 COMPLETED
Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks
GlaxoSmithKline n=617
NCT01313637 COMPLETED
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
GlaxoSmithKline n=1,493
NCT01054885 COMPLETED
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=1,226
NCT02105974 COMPLETED
Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=1,621
NCT01899742 COMPLETED
The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
GlaxoSmithKline n=497
NCT01777334 COMPLETED
The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
GlaxoSmithKline n=905
NCT02207829 COMPLETED
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
GlaxoSmithKline n=1,017
NCT01316900 COMPLETED
24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease
GlaxoSmithKline n=846
NCT01061671 TERMINATED
Simvastatin Therapy for Moderate and Severe COPD
University of Minnesota n=885
NCT02487446 COMPLETED
Efficacy and Safety Study of QVA149 in COPD Patients
Novartis Pharmaceuticals n=357
NCT01072149 COMPLETED
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
GlaxoSmithKline n=54
NCT01627327 COMPLETED
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
GlaxoSmithKline n=623
NCT02152605 COMPLETED
A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=498
NCT01387230 COMPLETED
Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD
GlaxoSmithKline n=206
NCT01957163 COMPLETED
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=619
NCT01009463 COMPLETED
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=1,626
NCT01879410 COMPLETED
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=700
NCT01336608 COMPLETED
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
GlaxoSmithKline n=446
NCT01323634 COMPLETED
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease
GlaxoSmithKline n=519
NCT01817764 COMPLETED
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=707
NCT02157935 COMPLETED
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
AstraZeneca n=2,026
NCT01328444 COMPLETED
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
GlaxoSmithKline n=349
NCT02148445 COMPLETED
Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
University of Kansas Medical Center n=398
NCT01822899 COMPLETED
A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=717
NCT01599871 COMPLETED
Low-dose Theophylline as Anti-inflammatory Enhancer in Severe Chronic Obstructive Pulmonary Disease
Hospital Son Espases n=70
NCT01978145 COMPLETED
A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=665
NCT01491802 COMPLETED
Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD
Queen's University n=17
NCT01353235 COMPLETED
Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Fekri Abroug n=317
NCT02305940 COMPLETED
Effects of Long Term Antibiotic Therapy on Exacerbation Rate in Stable COPD Patients
Imperial College London n=222
NCT01551758 COMPLETED
A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=2,802
NCT01437540 COMPLETED
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
AstraZeneca n=590
NCT00692198 COMPLETED
Long-term Oxygen Treatment Trial
National Heart, Lung, and Blood Institute (NHLBI) n=738
NCT02047448 COMPLETED
Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model
Wilkes University n=180
NCT01572792 COMPLETED
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca n=921
NCT01044459 COMPLETED
Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)
AstraZeneca n=605
NCT02165826 COMPLETED
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
AstraZeneca n=1,323
NCT01757015 WITHDRAWN
Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS
Novartis Pharmaceuticals
NCT02347072 COMPLETED
24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo
Pearl Therapeutics, Inc. n=80
NCT02454959 COMPLETED
Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD
Pearl Therapeutics, Inc. n=80
NCT02594722 COMPLETED
Metabolism and Oxygen Consumption During Functional Electrical Stimulation Cycling in COPD
University Hospital, Rouen n=25
NCT00642616 TERMINATED
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Mannkind Corporation n=34
NCT01316913 COMPLETED
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
GlaxoSmithKline n=872
NCT01245569 COMPLETED
A Study in Patients With Chronic Obstructive Pulmonary Disease
Chiesi Farmaceutici S.p.A. n=373
NCT01351792 TERMINATED
A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)
Chiesi Farmaceutici S.p.A. n=113
NCT01854645 COMPLETED
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
Pearl Therapeutics, Inc. n=2,103
NCT02195375 COMPLETED
Flutiform® Compared With Seretide® in the Treatment of COPD
Mundipharma Research Limited n=923
NCT01854658 COMPLETED
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)
Pearl Therapeutics, Inc. n=1,615
NCT02119286 COMPLETED
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
GlaxoSmithKline n=620
NCT01772147 COMPLETED
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
GlaxoSmithKline n=608
NCT01437397 COMPLETED
Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca n=1,692
NCT01970878 COMPLETED
Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)
Pearl Therapeutics, Inc. n=892
NCT01393145 WITHDRAWN
Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD
Ache Laboratorios Farmaceuticos S.A.
NCT01462942 COMPLETED
Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination
AstraZeneca n=2,443
NCT01313494 COMPLETED
A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:
AstraZeneca n=626
NCT01045161 COMPLETED
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
AstraZeneca n=544
NCT01192191 COMPLETED
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD
GlaxoSmithKline n=187
NCT01376245 COMPLETED
A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD
GlaxoSmithKline n=646
NCT01716520 COMPLETED
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
GlaxoSmithKline n=182
NCT01636713 COMPLETED
A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD
GlaxoSmithKline n=581
NCT01376388 COMPLETED
Long-term Safety Study for GSK573719/GW642444 in Japanese
GlaxoSmithKline n=131
NCT02085161 COMPLETED
To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways
Boehringer Ingelheim n=304
NCT00891462 COMPLETED
Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)
AstraZeneca n=561
NCT00970268 COMPLETED
Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)
AstraZeneca n=291
NCT01001494 COMPLETED
Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients
AstraZeneca n=828
NCT01462929 COMPLETED
Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca n=414
NCT01471171 COMPLETED
Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca n=112
NCT02268396 COMPLETED
Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD
Pearl Therapeutics, Inc. n=138
NCT01525615 COMPLETED
A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
Boehringer Ingelheim n=404
NCT01837927 WITHDRAWN
Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.
Novartis Pharmaceuticals
NCT00826683 COMPLETED
Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)
University Hospital, Limoges n=140
NCT01601977 COMPLETED
Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD) Patients
Patrick Murphy n=10
NCT02731846 WITHDRAWN
A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline
NCT01610037 COMPLETED
Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation
Novartis Pharmaceuticals n=1,215
NCT01782326 COMPLETED
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)
Novartis Pharmaceuticals n=3,362
NCT00990132 COMPLETED
Home Mechanical Ventilation vs Home Oxygen Therapy in COPD
Patrick Murphy n=116
NCT00789997 COMPLETED
TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial
Ottawa Hospital Research Institute n=81
NCT01996319 COMPLETED
Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.
Novartis Pharmaceuticals n=194
NCT01682863 COMPLETED
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Novartis Pharmaceuticals n=614
NCT01727141 COMPLETED
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
Novartis Pharmaceuticals n=1,042
NCT01697696 COMPLETED
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
Novartis Pharmaceuticals n=511
NCT01944176 COMPLETED
The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokine in COPD Patients
Mahidol University n=24
NCT01908140 COMPLETED
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca n=933
NCT00999908 COMPLETED
Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity
Novartis Pharmaceuticals n=54
NCT01012765 COMPLETED
Effect of Indacaterol on Inspiratory Capacity (IC)
Novartis Pharmaceuticals n=173
NCT01969721 COMPLETED
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
Boehringer Ingelheim n=229
NCT01694732 COMPLETED
Efficacy of Varenicline on Smoking Cessation at the Acute Phase of an Exacerbation of Chronic Obstructive Pulmonary Disease
University Hospital, Brest n=83
NCT01699685 COMPLETED
Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
Novartis Pharmaceuticals n=79
NCT00932646 COMPLETED
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Boehringer Ingelheim n=100
NCT02006732 COMPLETED
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
Boehringer Ingelheim n=809
NCT02455362 WITHDRAWN
Opioids for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease
Flinders University
NCT01964352 COMPLETED
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
Boehringer Ingelheim n=813
NCT02261350 TERMINATED
Post-hospitalisation Nutritional Support and Gait Speed in COPD
Royal Brompton & Harefield NHS Foundation Trust n=22
NCT01071161 COMPLETED
The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough
Isala n=84
NCT01533935 COMPLETED
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
Boehringer Ingelheim n=291
NCT01533922 COMPLETED
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
Boehringer Ingelheim n=295
NCT01431274 COMPLETED
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
Boehringer Ingelheim n=2,624
NCT01559116 COMPLETED
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
Boehringer Ingelheim n=219
NCT01431287 COMPLETED
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
Boehringer Ingelheim n=2,539
NCT01712516 COMPLETED
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
Novartis Pharmaceuticals n=1,001
NCT01536262 COMPLETED
Japan Long-term Safety for Tiotropium Plus Olodaterol
Boehringer Ingelheim n=122
NCT01385696 COMPLETED
Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients
Almirall, S.A. n=130
NCT01857323 COMPLETED
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
Teva Branded Pharmaceutical Products R&D, Inc. n=317
NCT01915784 COMPLETED
Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD
Almirall, S.A. n=128
NCT01499485 COMPLETED
Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation.
Hospital Son Llatzer n=140
NCT01709903 COMPLETED
A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149
Novartis Pharmaceuticals n=744
NCT01715298 COMPLETED
NVA237 BID Versus Placebo Twelve-week Efficacy Study
Novartis Pharmaceuticals n=432
NCT01009099 COMPLETED
Reducing Dynamic Hyperinflation Through Breathing Retraining
US Department of Veterans Affairs n=119
NCT01513460 COMPLETED
Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals n=773
NCT01696058 COMPLETED
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
Boehringer Ingelheim n=1,137
NCT01604278 COMPLETED
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=449
NCT02278523 COMPLETED
The Respiratory Physiology Variation of COPD Patients in Inspiratory Muscle Training
Guangzhou Institute of Respiratory Disease n=12
NCT01019694 COMPLETED
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
Boehringer Ingelheim n=470
NCT01658020 COMPLETED
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg
Dong Wha Pharmaceutical Co. Ltd. n=345
NCT01155310 TERMINATED
Efficacy of Helium/Oxygen Compared to Air/Oxygen in Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Air Liquide Santé International n=446
NCT01694771 COMPLETED
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
Boehringer Ingelheim n=1,134
NCT01566604 COMPLETED
Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals n=460
NCT01040130 COMPLETED
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I
Boehringer Ingelheim n=151
NCT01040793 COMPLETED
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II
Boehringer Ingelheim n=157
NCT00931385 COMPLETED
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Boehringer Ingelheim n=99
NCT01040689 COMPLETED
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
Boehringer Ingelheim n=108
NCT01040728 COMPLETED
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
Boehringer Ingelheim n=122
NCT00793624 COMPLETED
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
Boehringer Ingelheim n=906
NCT00796653 COMPLETED
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
Boehringer Ingelheim n=937
NCT01126437 COMPLETED
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
Boehringer Ingelheim n=17,183
NCT01574651 COMPLETED
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=934
NCT01070784 COMPLETED
A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan
AstraZeneca n=328
NCT01613326 COMPLETED
Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=657
NCT02079753 COMPLETED
Single Portable Pulse-dose-conserving Device vs. Combined Use of Stationary and Portable.
Hospital Son Espases n=38
NCT01868009 COMPLETED
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
GlaxoSmithKline n=287
NCT02070133 COMPLETED
Efficacy of Simvastatin for the Treatment of COPD
Hospital Universitari Son Dureta n=18
NCT01529632 COMPLETED
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=193
NCT00977873 COMPLETED
Trial of Vitamin D Supplementation in Chronic Obstructive Pulmonary Disease
Barts & The London NHS Trust n=240
NCT01285492 COMPLETED
Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=160
NCT01490125 COMPLETED
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=247
NCT00951782 COMPLETED
Deep High-Frequency Repetitive Transcranial Magnetic Stimulation for Smoking Cessation
BeerYaakov Mental Health Center n=115
NCT01120691 COMPLETED
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
Novartis Pharmaceuticals n=2,224
NCT01232894 COMPLETED
12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
Novartis Pharmaceuticals n=90
NCT01320566 TERMINATED
A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema
Aeris Therapeutics n=18
NCT01908933 WITHDRAWN
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
Aeris Therapeutics
NCT01834885 WITHDRAWN
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Novartis Pharmaceuticals
NCT01860066 WITHDRAWN
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Novartis Pharmaceuticals
NCT00909779 COMPLETED
Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects
Sumitomo Pharma America, Inc. n=841
NCT00579046 WITHDRAWN
Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease
Assistance Publique - Hôpitaux de Paris
NCT00826163 COMPLETED
Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients
Mahidol University n=20
NCT01202188 COMPLETED
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=2,144
NCT01636401 COMPLETED
Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Daewoong Pharmaceutical Co. LTD.
NCT01315249 COMPLETED
QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=523
NCT00914810 COMPLETED
Effect of Supplemental Vitamin D on Skeletal Muscle Function in Chronic Obstructive Pulmonary Disease (COPD) Patients
Minneapolis Veterans Affairs Medical Center n=39
NCT01294787 COMPLETED
Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=85
NCT01120717 COMPLETED
A Study to Assess the Long-term Safety of QVA149
Novartis Pharmaceuticals n=339
NCT00982891 COMPLETED
Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD)
Nova Scotia Health Authority n=45
NCT01119937 COMPLETED
Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients
Novartis Pharmaceuticals n=211
NCT01047553 COMPLETED
Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients
AstraZeneca n=251
NCT01480882 COMPLETED
Efficacy and Safety Study of a Percussion Device to Mobilise Sputum From Respiratory Passage
Penang Hospital, Malaysia n=20
NCT01069289 COMPLETED
Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
AstraZeneca n=1,293
NCT01045213 COMPLETED
Integrated Care Program for Chronic Obstructive Pulmonary Disease
University of Colorado, Denver n=100
NCT00929110 COMPLETED
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
Novartis n=1,066
NCT01204034 COMPLETED
Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
University Hospital, Antwerp n=29
NCT01154127 COMPLETED
Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=108
NCT01005901 COMPLETED
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
Novartis n=1,324
NCT01523470 COMPLETED
Withdrawal of Non-invasive Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Acute Hypercapnic Respiratory Failure
United Christian Hospital n=60
NCT01135966 COMPLETED
Resistance Training in Patients With Chronic Obstructive Lung Disease (COPD): Whole Body Vibration Versus Conventional Resistance Training
University Hospital, Ghent n=62
NCT00876694 COMPLETED
Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=186
NCT01181466 COMPLETED
AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema
Aeris Therapeutics n=20
NCT00669617 COMPLETED
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Novartis n=89
NCT00877383 COMPLETED
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals n=1,142
NCT00677807 COMPLETED
Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Novartis n=415
NCT00900731 COMPLETED
A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=1,598
NCT01068600 COMPLETED
Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks
Novartis n=318
NCT01089127 COMPLETED
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=552
NCT00622635 COMPLETED
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=68
NCT00846586 COMPLETED
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals n=1,134
NCT00821093 COMPLETED
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=1,123
NCT00624286 COMPLETED
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Novartis n=416
NCT00615030 COMPLETED
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Novartis n=96
NCT00615459 COMPLETED
A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control
Novartis n=169
NCT00792805 COMPLETED
Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=563
NCT00620022 COMPLETED
The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Novartis n=90
NCT00794157 COMPLETED
Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals n=347
NCT01364181 COMPLETED
The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
Seoul National University Hospital n=23
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only